Boehringer Ingelheim To Focus On Precision Psychiatry In CNS

R&D Mission: Explore Brain’s Biological Circuitry

 
• By Sten Stovall
  
Generate a summary of this article
Listen to this article
Beta

Boehringer Ingelheim will increasingly use external collaborations in its search for new treatment options for neuropsychiatric diseases, its CNS R&D head tells Scrip.

Brain Circuitry
Boehringer Ingelheim is pursing CNS innovation via collaborations, too. • Source: Shutterstock

The emerging science of precision psychiatry – which aims to understand and directly treat the biology behind psychotic disorders such as schizophrenia – lies at the core of Boehringer Ingelheim GmbH’s central nervous system research and development program. Its freshly signed collaboration with the US-based Lieber Institute for Brain Development should advance those efforts, BI’s recently-appointed head of CNS disease R&D Hugh Marston told Scrip.

“BI's interest in terms of our CNS focus at the moment is very much in the area of psychiatry,” said...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.